Regulatory & Reimbursement
FDA Output April 2021
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in April 2021. Updated April 30.
Welcome to MyStrategist, the digital home for Market Pathways.
Market Pathways covers the people, challenges, and opportunities impacting the global medtech regulatory, reimbursement, and policy communities. We invite you to explore our coverage. Think Strategically.
Subscribe Today
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Regulatory & Reimbursement
FDA Output May 2021
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in May 2021. Updated May 13.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
Knocking on Your Virtual Door: A Guide to FDA’s Remote Regulatory Assessments
FDA’s medical device inspection branch officially launched what it calls the “Remote Regulatory Assessments” program in February. Trang Cox, a device inspector at FDA, recently provided an overview of how to participate in the program and what to expect.